12,372 trials
Alzheimers Disease · Dementia · Alzheimers Disease, Familial
Primary: Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE); — 1.063…
Myelodysplastic Syndrome · Leukemia, Myelomonocytic, Chronic · Leukemia, Myeloid, Acute
Primary: Event-Free Survival (EFS) — 15.7; 17.7 months — p==0.557
Crohn's Disease
Primary: Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10 — 24.3; 19.4 percentage of participants — p==0.347
Non-segmental Vitiligo
Primary: Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24 — 30.9; 11.4 percentage of…
Multiple Sclerosis · Neurogenic Bladder
Primary: Change in Bladder Control Scale (BLCS) — -9 score on a scale — p=0.002
Major Depressive Disorder
Primary: Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) Total Score — -13.4; -13.8; -14.8 score on a scale — p=0.6798
Spondyloarthritis
Primary: Study 1: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society 40 (ASAS40) Response at Week 14 — 18.2; 44.5 percentage of…
Non-segmental Vitiligo
Primary: Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24 — 29.8; 7.4 percentage of…
Hereditary Angioedema (HAE)
Primary: Number of Participants Achieving Attack-Free Status for the Efficacy Evaluation Period of Day 0 Through Day 182 — 5 Participants
Lumbosacral Radicular Pain
Primary: Mean Change From Baseline (Day 1) to Week 4 in the Mean Numeric Pain Rating Scale (NPRS) Average Pain Score in the Affected Leg — -2.34; -1.16 Change in score on a scale…
Pulmonary Arterial Hypertension
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) up to 3 Days After Study Intervention Discontinuation — 684 Participants
HIV Infection
Primary: Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48 — 0.0; 1.5 Percentage of Participants — p=<.001
Acne Vulgaris
Primary: Number of Participants With Treatment RelatedAdverse Events — 10; 9; 0; 0 Participants
Atopic Dermatitis
Primary: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 — 10.8; 33.2 percentage of…
Tobacco Use Disorder
Primary: Feasibility as Indicated by Self-reported Adherence to Study Cigarettes. — 7.1; 7.3; 10.4; 13.3 Percent non-study cigarettes per day